MDxHealth to Present at the 2013 BIO CEO & Investor Conference

MDxHealth to Present at the 2013 BIO CEO & Investor Conference 
IRVINE, CA, and LIEGE, BELGIUM -- (Marketwire) -- 02/04/13 -- 
MDxHealth SA (EURONEXT BRUSSELS: MDXH), a leading molecular
diagnostic company that develops and commercializes epigenetic tests
to support cancer diagnosis and treatment, today announced that Dr.
Jan Groen, the Company's Chief Executive Officer, will present at the
15th Annual BIO CEO & Investor Conference on Monday, February 11th
2013 at 3.00 pm Eastern Time at the Waldorf-Astoria in New York, NY.  
About the BIO CEO & Investors Conference
 The Annual BIO CEO &
Investor Conference is the largest investor conference focused on
established and emerging publicly traded biotech companies. This
year's conference will feature corporate presentations from more than
130 leading biotechnology and pharmaceutical companies. The
presenting companies consist of a selection of mid- to large-cap
established public companies from around the globe, who typically
have a clinical stage program centered around therapeutics, molecular
diagnostics, or a platform technology, as well as an upcoming
clinical, regulatory, or corporate catalyst. More information on the
conference can be found at www.bio.org. 
About MDxHealth
 MDxHealth is a molecular diagnostics company that
develops and commercializes advanced epigenetic tests for cancer
assessment and the personalized treatment of patients. The company's
first commercial product, the ConfirmMDx for Prostate Cancer test,
has been shown to help distinguish patients who have a true-negative
biopsy from those who may have occult cancer. MDxHealth helps to
address a large and growing unmet medical need for better cancer
diagnosis and treatment information. The company has a proprietary
platform and a strong epigenetic product pipeline focused on the
development of products for brain and lung cancers. The company is
based in Irvine, California with a European headquarters in Liege,
Belgium. For more information visit MDxHealth website at
www.mdxhealth.com. 
This press release contains forward-looking statements and estimates
with respect to the anticipated future performance of MDxHealth and
the market in which it operates. Such statements and estimates are
based on assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable but may
not prove to be correct. Actual events are difficult to predict, may
depend upon factors that are beyond the company's control, and may
turn out to be materially different. MDxHealth expressly disclaims
any obligation to update any such forward-looking statements in this
release to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any
such statement is based unless required by law or regulation. 
BIO CEO ENG : http://hugin.info/137314/R/1675036/545586.pdf  
Contacts  
Company : 
Dr Jan Groen
CEO 
MDxHealth 
US: +1 949 812 6979 
BE: +32 4 364 20 70 
info@mdxhealth.com  
Media : 
Mike Sinclair
Halsin Partners
UK: +44 20 7318 2955 
US: +1 646 378 2952
Cell: +44 7968 022075
msinclair@halsin.com 
Investors :
Seth Lewis
The Trout Group
US : + 1 646 378 2952
slewis@troutgroup.com